Solid Biosciences Inc. entered into a securities purchase agreement with certain institutional accredited investors to issue common stock and Pre-Funded warrants for a aggregate proceeds of.
Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) COO David T. Howton sold 5,367 shares of Solid Biosciences stock in a transaction on Monday, December 4th. The stock was sold at an average price of $2.78, for a total value of $14,920.26. Following the sale, the chief operating officer now owns 7,684 shares in the […]
Life sciences company Solid Biosciences Inc. (SLDB) announced Thursday that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003, the company's next-generation Duchenne muscular dystrophy gene therapy candidate.